Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
August 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval...